---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-139517"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:53:32.338454+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio prices $100M public offering of common stock and warrants to fund rese-cel development

## Summary
- Offering includes 39.2M shares and 50M warrants at combined price of $2.00 per unit; net proceeds ~$94M.
- Also offers 10.8M pre-funded warrants at $1.99999 per unit for certain investors.
- Underwriters have 30-day option to purchase up to an additional 15M shares and/or warrants.
- Proceeds to fund expanded clinical development of rese-cel, including potential registrational studies, and manufacturing readiness.
- Cash runway expected into second half of 2026 based on current operating plan.

## SEC filing metadata
- accession: 0001193125-25-139517
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312525139517/0001193125-25-139517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312525139517/d828604d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-139517
- JSON: https://secwatch.observer/filing/0001193125-25-139517.json
- Plain text: https://secwatch.observer/filing/0001193125-25-139517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.